Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery | News
Search Refinements

Drug Delivery News

View news from other Pharmaceutical sectors:
1-15 of 2301 results
UK’s NICE makes Nivolumab available for head and neck cancer patients
UK’s National Institute for Health and Care Excellence (NICE) has made nivolumab (Opdivo) made by Bristol-Myers Squibb available for patients with head and neck cancer who did not respond to chemotherapy within six months, and the cancer has spread to other parts of the body.
Drug Research > Drug Delivery > News
FDA advisory panel recommends approval of GSK’s shingles vaccine Shingrix
By PBR Staff Writer
An advisory committee of the US Food and Drug Administration (FDA) has recommended the approval of GlaxoSmithKline’s (GSK) Shingrix vaccine for the prevention of herpes zoster (shingles) in adults aged 50 years and over.
Drug Research > Drug Delivery > News
HitGen, Takeda enter DNA-encoded library based drug discovery research collaboration
HitGen announced that the company has entered into a research collaboration with Takeda Pharmaceutical Company to discover novel small molecule leads for multiple targets in Takeda’s therapeutic areas of interest.
Drug Research > Drug Delivery > News
Takeda, Cardurion Pharmaceuticals form cardiovascular development partnership
Takeda Pharmaceutical and Cardurion Pharmaceuticals have created a new cardiovascular development partnership.
Drug Research > Drug Delivery > News
Study says machine learning algorithms can help predict schizophrenia
By PBR Staff Writer
A new study has found that artificial intelligence (AI) and machine learning algorithms helped predict instances of schizophrenia with 74% accuracy.
Drug Research > Drug Delivery > News
GlobalData says acute myeloid leukemia market will cross $1.5bn by 2026
The acute myeloid leukemia (AML) market in the seven major countries (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will grow more than three times from $406m in 2016 to more than $1.5bn by 2026, reflecting a compound annual growth rate of 14%, as per research and consulting firm GlobalData.
Drug Research > Drug Delivery > News
Sarepta, BioMarin settle patent litigation over DMD exon-skipping drugs
By PBR Staff Writer
Sarepta Therapeutics and BioMarin Pharmaceutical have settled a global patent litigation relating to the use of the former’s Exondys 51 and all future exon-skipping products for the treatment of Duchenne muscular dystrophy (DMD).
Drug Research > Drug Delivery > News
Sanofi to buy US vaccines biotechnology firm Protein Sciences
By PBR Staff Writer
French drugmaker Sanofi has agreed to acquire US vaccines biotechnology firm Protein Sciences for around $650m.
Drug Research > Drug Delivery > News
NHS patients in England getting early access to new drugs for lung cancer and sarcoma
NICE's Cancer Drugs Fund (CDF) is driving early access to new drugs for lung cancer and sarcoma for NHS patients in England.
Drug Research > Drug Delivery > News
AstraZeneca recalls physician sample bottles of BRILINTA heart drug
AstraZeneca said that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA (ticagrelor) 90mg tablets as a precautionary measure.
Drug Research > Drug Delivery > News
EC launches probe into Aspen's pricing practices for cancer drugs
The European Commission has initiated a formal investigation to see whether Aspen Pharma had excessively priced five life-saving cancer medicines.
Drug Research > Drug Delivery > News
Clinigen, Tesaro partner to supply ovarian cancer drug in Europe
Clinigen Group’s Idis Managed Access division and Tesaro have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe for niraparib, the investigational PARP 1/2 inhibitor, for patients with recurrent ovarian cancer.
Drug Research > Drug Delivery > News
Sunesis withdraws leukemia drug marketing application in Europe
Sunesis Pharmaceuticals said it will withdraw its European Marketing Authorization Application (MAA) for vosaroxin as a therapy for acute myeloid leukemia (AML) both in relapsed and refractory forms in patients aged 60 years and older.
Drug Research > Drug Delivery > News
Teva launches generic Vytorin tablets in US
Teva Pharmaceutical Industries has launched the generic Vytorin (ezetimibe and simvastatin) tablets in the US.
Drug Research > Drug Delivery > News
Lack of demand forces uniQure to withdraw Glybera gene therapy in Europe
By PBR Staff Writer
uniQure said that due to low patient demand it will not pursue a renewal of its European marketing authorization for Glybera (alipogene tiparvovec), which is due to expire on 25 October.
Drug Research > Drug Delivery > News
1-15 of 2301 results